Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Raise $500M Through Senior Notes Offering

NEW YORK – Agilent Technologies said on Monday that it has priced an underwritten, registered public offering of a series of its senior notes, in an aggregate principal amount of $500 million.

In a filing with the US Securities and Exchange Commission, the company said that the notes will mature in June 2030 and will bear interest at an annual rate of 2.1 percent. The offering is expected to close on June 4, and Agilent is expecting net proceeds of about $494.3 million.

The company plans to use the funds from the offering for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility.

Bank of America Securities, Mizuho Securities USA, and Wells Fargo Securities are acting as joint book-running managers.

Agilent's shares were up a fraction of 1 percent to $90.15 in mid-morning trading on the New York Stock Exchange. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.